{{about|the cannabinoid drug|the South Korean girl band|2NE1|the metabotropic glutamate receptor antagonist|APICA (drug)}}
{{Drugbox
| IUPAC_name = ''N''-(1-adamantyl)-1-pentylindole-3-carboxamide
| image = APICA_structure.png

<!--Clinical data-->
| tradename =  
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = Schedule II
| legal_DE = Anlage II
| legal_UK = <!-- GSL         / P       / POM / CD / Class A, B, C -->
| legal_US =
| legal_status = Illegal in China and Japan
| routes_of_administration =

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 1345973-50-3
| ATC_prefix =  
| ATC_suffix =  
| PubChem = 71308155
| ChemSpiderID = 29341717
| smiles = CCCCCn1cc(C(=O)NC23CC4CC(CC(C4)C2)C3)c5ccccc15
| StdInChI          = 1S/C24H32N2O/c1-2-3-6-9-26-16-21(20-7-4-5-8-22(20)26)23(27)25-24-13-17-10-18(14-24)12-19(11-17)15-24/h4-5,7-8,16-19H,2-3,6,9-15H2,1H3,(H,25,27)
| StdInChIKey       = MDJYHWLDDJBTMX-UHFFFAOYSA-N

<!--Chemical data-->
| C=24 | H=32 | N=2 | O=1 
| molecular_weight = 364.522 g/mol
}}

'''APICA''' ('''2NE1''', '''SDB-001''', '''''N''-(1-adamantyl)-1-pentyl-1''H''-indole-3-carboxamide''') is an [[indole]] based drug that acts as a potent [[agonist]] for the [[cannabinoid receptor]]s.<ref>{{cite journal | url=http://www.sciencedirect.com/science/article/pii/S0379073815005368 | title=Behavioural And Pharmacological Characterization Of A Novel Cannabinomimetic Adamantane-Derived Indole, Apica, And Considerations On The Possible Misuse As A Psychotropic Spice Abuse, In C57bl/6 J Mice |author1=Carla Cannizzaro |author2=Ginevra Malta |author3=Antonina Argo |author4=Anna Brancato |author5=Gabriella Roda |author6=Eleonora Casagni |author7=Laura Fumagalli |author8=Ermanno Valoti |author9=Rino Froldi |author10=Paolo Procaccianti |author11=Veniero Gambaro | journal=Forensic Science International | date=January 2016 | doi=10.1016/j.forsciint.2015.12.035 | volume=265 | pages=6–12}}</ref>

It had never previously been reported in the scientific or patent literature, and was first identified by laboratories in Japan in March 2012 as an ingredient in [[synthetic cannabis]] smoking blends, along with its indazole derivative [[APINACA]] (sold as "AKB48").<ref>{{Cite journal | last1 = Uchiyama | first1 = N. | last2 = Kawamura | first2 = M. | last3 = Kikura-Hanajiri | first3 = R. | last4 = Goda | first4 = Y. | title = Identification of two new-type synthetic cannabinoids, ''N''-(1-adamantyl)-1-pentyl-1''H''-indole-3-carboxamide (APICA) and ''N''-(1-adamantyl)-1-pentyl-1''H''-indazole-3-carboxamide (APINACA), and detection of five synthetic cannabinoids, AM-1220, AM-2233, AM-1241, CB-13 (CRA-13), and AM-1248, as designer drugs in illegal products | doi = 10.1007/s11419-012-0136-7 | journal = Forensic Toxicology | volume = 30 | issue = 2 | pages = 114–125 | year = 2012 | pmid =  | pmc = }}</ref>

Structurally it closely resembles cannabinoid compounds from patent [http://patentscope.wipo.int/search/en/detail.jsf?docId=WO2003035005 WO 2003/035005] but with an indole core instead of indazole, and a simple pentyl chain on the indole 1-position.

Pharmacological testing determined APICA to have an [[IC50|IC<sub>50</sub>]] of 175&nbsp;nM at CB<sub>1</sub>, only slightly less potent than JWH-018 which had an IC<sub>50</sub> of 169&nbsp;nM, but over four times more tightly binding than APINACA, which had an IC<sub>50</sub> of 824&nbsp;nM.<ref>{{Cite journal | last1 = Uchiyama | first1 = N. | last2 = Kawamura | first2 = M. | last3 = Kikura-Hanajiri | first3 = R. | last4 = Goda | first4 = Y. | title = URB-754: A new class of designer drug and 12 synthetic cannabinoids detected in illegal products | doi = 10.1016/j.forsciint.2012.08.047 | journal = Forensic Science International | volume = 227 | issue = 1–3 | pages = 21–32 | year = 2012 | pmid =  23063179| pmc = }}</ref> The first published synthesis and pharmacological evaluation of APICA revealed that it acts as a full agonist at CB<sub>1</sub> ([[EC50|EC<sub>50</sub>]]&nbsp;=&nbsp;34&nbsp;nM) and CB<sub>2</sub> receptors (EC<sub>50</sub>&nbsp;=&nbsp;29&nbsp;nM).<ref name="Banister">{{Cite journal | last1 = Banister | first1 = S. D. | last2 = Wilkinson | first2 = S. M. | last3 = Longworth | first3 = M. | last4 = Stuart | first4 = J. | last5 = Apetz | first5 = N. | last6 = English | first6 = K. | last7 = Brooker | first7 = L. | last8 = Goebel | first8 = C. | last9 = Hibbs | first9 = D. E. | last10 = Glass | first10 = M. | last11 = Connor | first11 = M. | last12 = McGregor | first12 = I. S. | last13 = Kassiou | first13 = M. | title = The synthesis and pharmacological evaluation of adamantane-derived indoles: Novel cannabimimetic drugs of abuse | doi = 10.1021/cn400035r | journal = ACS Chemical Neuroscience | volume = 4 | issue = 7 | pages = 130403084729007 | year = 2013 | pmid =  23551277| pmc = 3715837}}</ref> Furthermore, APICA possesses cannabis-like effects in rats, and appears to be less potent than [[JWH-018]] but more potent than THC.<ref name="Banister" /><ref>{{Cite journal | doi = 10.1021/acschemneuro.5b00107| title = Effects of Bioisosteric Fluorine in Synthetic Cannabinoid Designer Drugs JWH-018, AM-2201, UR-144, XLR-11, PB-22, 5F-PB-22, APICA, and STS-135| journal = ACS Chemical Neuroscience| pages = 150508124201002| year = 2015| last1 = Banister | first1 = S. D. | last2 = Stuart | first2 = J. | last3 = Kevin | first3 = R. C. | last4 = Edington | first4 = A. | last5 = Longworth | first5 = M. | last6 = Wilkinson | first6 = S. M. | last7 = Beinat | first7 = C. | last8 = Buchanan | first8 = A. S. | last9 = Hibbs | first9 = D. E. | last10 = Glass | first10 = M. | last11 = Connor | first11 = M. | last12 = McGregor | first12 = I. S. | last13 = Kassiou | first13 = M. | volume=6 | pmid=25921407}}</ref>

==Legal Status==

As of October 2015 APICA is a controlled substance in China.<ref>{{cite web | url=http://www.sfda.gov.cn/WS01/CL0056/130753.html | title=关于印发《非药用类麻醉药品和精神药品列管办法》的通知 | publisher=China Food and Drug Administration | date=27 September 2015 | language=Chinese | accessdate=1 October 2015}}</ref>

==See also==
{{div col|colwidth=30em}}
* [[5F-AB-PINACA]]
* [[5F-ADB]]
* [[5F-AMB]]
* [[5F-APINACA]]
* [[AB-FUBINACA]]
* [[AB-CHFUPYCA]]
* [[AB-CHMINACA]]
* [[AB-PINACA]]
* [[ADAMANTYL-THPINACA]]
* [[ADB-CHMINACA]]
* [[ADB-FUBINACA]]
* [[ADB-PINACA]]
* [[ADBICA]]
* [[MDMB-CHMICA]]
* [[SDB-006]]
* [[STS-135 (drug)]]
* [[PX-3]]
{{Div col end}}

==References==
{{reflist}}

{{Cannabinoids}}

[[Category:Cannabinoids]]
[[Category:Designer drugs]]
[[Category:Indoles]]
[[Category:Indolecarboxamides]]
[[Category:Adamantanes]]


{{cannabinoid-stub}}